InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.030 -0.006 (-16.67%)+
Announcement
Release
22 Jul 2026 9:35AM
Price at Release
$0.036
Full Release
download
Summary
Patrys Limited (ASX: PAB) has made significant progress in advancing RLS-2202 towards the Phase 1A clinical trial, achieving key operational milestones such as appointing CMAX as the trial site and Alithia Life Sciences as the CRO. The company is on track to dose the first participant in Q3 2026, pending necessary approvals. A successful capital raise of $3.1 million during the quarter has fortified Patrys' financial position, supporting ongoing clinical and regulatory activities. The quarter concluded with a cash balance of A$3.36 million, reflecting the company's continued investment in clinical advancements and intellectual property protection.
Key Points
  • Patrys advances RLS-2202 toward Phase 1A clinical trial
  • CMAX appointed as Phase 1A clinical trial site
  • Alithia Life Sciences appointed as CRO
  • First participant dosing targeted for Q3 2026
  • Successful $3.1 million capital raise completed
  • Quarterly cash flow report shows A$3.36 million cash balance at quarter end
  • Focus on regulatory and clinical planning, and intellectual property protection
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.